BioRestorative Therapies (BRTX) Income towards Parent Company (2010 - 2025)

BioRestorative Therapies (BRTX) has 16 years of Income towards Parent Company data on file, last reported at -$26.4 million in Q4 2025.

• Quarterly Income towards Parent Company fell 866.17% year-over-year to -$26.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$39.2 million (down 233.85% YoY) and the FY2025 annual result came in at -$38.2 million, up 6.73% from the prior year.
• Income towards Parent Company eased to -$26.4 million in Q4 2025, from -$3.7 million in the prior quarter.
• In the past five years, Income towards Parent Company ranged from a high of -$2.3 million in Q3 2024 to a low of -$26.4 million in Q4 2025.
• A 5-year average of -$5.6 million and a median of -$4.2 million in 2021 frame the typical range for Income towards Parent Company.
• Annual changes were most pronounced in 2021 — Income towards Parent Company tumbled 1178.06% — and 2022, when it soared 66.25%.
• Tracing BRTX's Income towards Parent Company over 5 years: stood at -$4.0 million in 2021, then decreased by 16.64% to -$4.7 million in 2022, then surged by 30.91% to -$3.3 million in 2023, then advanced by 16.22% to -$2.7 million in 2024, then plunged by 866.17% to -$26.4 million in 2025.
• The last three Income towards Parent Company figures came in at -$26.4 million (Q4 2025), -$3.7 million (Q3 2025), and -$3.7 million (Q2 2025), per Business Quant data.